Eidos Therapeutics
0 followers
Eidos Therapeutics, a subsidiary of BridgeBio Pharma, is developing AG10 as a targeted therapeutic for transthyretin amyloidosis. The company’s singular mission is to improve and prolong the lives of patients suffering from this disease. Launched in 2016 after years of research supported by Stanfor... Read more
Org chart
Neil Kumar
Chief Executive Officer
Neil Kumar
Collapse
Jonathan Fox
MD, PhD, FACC
Matt Outten
Chief Commercial Officer
Ananth Sridhar
Senior Vice President, Corporate Development
Isabella Graef
Scientific Co-Founder
Jonathan Cascon
Director, QA
Mamoun Alhamadsheh
Scientific co-Founder
Satish Rao
Senior Vice President, DMPK
Stuart Heminway
Senior Vice President, Regulatory Affairs, BridgeBio Cardiorenal
Suresh Siddhanti
Vice President, Clinical Development
